Study Conduct

Clinerion and ASUS Life partner in Taiwan

Thursday, February 16, 2017

Clinerion and ASUS Life signed a strategic alliance. Clinerion and ASUS Life, together with the Show Chwan Healthcare System, will deliver innovative services for the efficient running of clinical trials, clinical patient recruitment, market access and real-world evidence in Taiwan.

[Read More]

Study: Quality of randomized control trials not measuring up

Wednesday, February 8, 2017

A majority of healthcare studies are conducted using a randomized control trial (RCT). These trials randomly assign participants into groups who either receive or do not receive treatment. However, until the mid-1990s, some of these studies were falling victim to inadequate reporting, thereby causing confusing and potentially biased results. Reviewing the quality of RCTs in various surgical specialties by using standardized methods is becoming a common practice.

[Read More]

Southern Cancer Center joins The US Oncology Network

Thursday, February 2, 2017

Southern Cancer Center, a physician-owned multi-site medical oncology practice serving the Alabama Gulf Coast region, has joined The US Oncology Network. The Network provides strong and comprehensive practice management capabilities and value-based care expertise that are critical for independent practices such as Southern Cancer Center navigating today’s challenging healthcare landscape. The Network is supported by McKesson Specialty Health, an industry provider of solutions that empower the community patient care delivery system to advance the science, technology and quality of care. Southern Cancer Center and The US Oncology Network share a vision of keeping independent physician groups strong and viable, while aiming to improve patient health.

[Read More]

Charles River Associates acquires C1 Consulting

Wednesday, February 1, 2017

Charles River Associates (CRA), a provider of economic, financial, and management consulting services, has acquired substantially all of the assets of C1 Consulting, a life sciences strategy consulting firm that helps pharmaceutical and biotech clients maximize their business potential through the development of highly tailored commercialization strategies based on advanced analytics, customer insights and therapy area expertise. The newly acquired team will join CRA’s Life Sciences Practice and provide additional breadth, depth, and scale to CRA’s client offerings across the industry. Financial terms of the acquisition were not disclosed. CRA expects the acquisition to be accretive to earnings in fiscal 2017.

[Read More]

Perlara partners with third patient advocacy group

Tuesday, January 31, 2017

Perlara, a global patient portal and drug discovery platform company for the one in 10 families affected by rare disease, has announced the formation of a PerlQuest partnership with Michigan-based Maggie’s PMM2-CDG Cure. PMM2-CDG, formerly known as congenital disorder of glycosylation type 1a, is caused by mutations in the evolutionarily conserved gene PMM2. There are currently no FDA approved treatments for PMM2-CDG.

[Read More]

Align Biopharma launched as industry standards group

Monday, January 30, 2017

Six of the top 25 largest global pharmaceutical companies announced the formation of Align Biopharma, a new group dedicated to setting technology standards that will make it faster and easier for healthcare professionals (HCPs) to connect with the life sciences industry. Founding members, with input from across the industry, will develop open standards and solutions for companies to streamline how HCPs get the drug and treatment information they need to deliver improved care to patients.

[Read More]

PhRMA launches media initiative

Tuesday, January 24, 2017

The Pharmaceutical Research and Manufacturers of America (PhRMA) has launched a national, multi-year advertising and public affairs initiative on behalf of America’s biopharmaceutical companies. The campaign, GOBOLDLY, will showcase the industry’s unsung heroes driving cutting-edge advances in science and highlight the tremendous opportunity that exists to tackle our most complex and devastating health conditions. 

[Read More]

DaVita, Prism choose Verified Clinical Trials to prevent duplicate enrollment

Friday, January 20, 2017

DaVita Clinical Research (DCR), a specialty CRO with services spanning the full spectrum of drug and device development, and Prism Clinical Research, a provider of fully integrated clinical research services to pharma/device companies and clinicians, have announced Verified Clinical Trials (VCT) has been selected by both companies as an exclusive provider to further prevent duplicate enrollment in clinical trials.

[Read More]

Interface Clinical Research launches new clinical trials model

Wednesday, January 18, 2017

New clinical trials company Interface Clinical Research outlined a new model for running primary care clinical trials. Interface will work in partnership with GP practices across the U.K. to deliver large numbers of suitable patients for phase III and IV clinical trials. Typically, 48% of sites used in a clinical trial fail to recruit a single patient. Interface believe they have the capability to recruit hundreds of patients per site.

[Read More]